Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Prevention Research
Cancer Prevention Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Research Article

Involvement of Epigenetics and EMT-Related miRNA in Arsenic-Induced Neoplastic Transformation and Their Potential Clinical Use

Christina Michailidi, Masamichi Hayashi, Sayantan Datta, Tanusree Sen, Kaitlyn Zenner, Oluwadamilola Oladeru, Mariana Brait, Evgeny Izumchenko, Alexander Baras, Christopher VandenBussche, Maria Argos, Trinity J. Bivalacqua, Habibul Ahsan, Noah M. Hahn, George J. Netto, David Sidransky and Mohammad Obaidul Hoque
Christina Michailidi
1Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins School of Medicine, Johns Hopkins University, Baltimore, Maryland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Masamichi Hayashi
1Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins School of Medicine, Johns Hopkins University, Baltimore, Maryland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sayantan Datta
1Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins School of Medicine, Johns Hopkins University, Baltimore, Maryland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tanusree Sen
1Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins School of Medicine, Johns Hopkins University, Baltimore, Maryland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kaitlyn Zenner
1Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins School of Medicine, Johns Hopkins University, Baltimore, Maryland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Oluwadamilola Oladeru
1Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins School of Medicine, Johns Hopkins University, Baltimore, Maryland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mariana Brait
1Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins School of Medicine, Johns Hopkins University, Baltimore, Maryland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Evgeny Izumchenko
1Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins School of Medicine, Johns Hopkins University, Baltimore, Maryland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexander Baras
2Department of Pathology, Johns Hopkins University, Baltimore, Maryland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christopher VandenBussche
2Department of Pathology, Johns Hopkins University, Baltimore, Maryland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Maria Argos
3Department of Health Studies, The University of Chicago, Chicago, Illinois.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Trinity J. Bivalacqua
4Department of Urology, Johns Hopkins University, Baltimore, Maryland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Habibul Ahsan
3Department of Health Studies, The University of Chicago, Chicago, Illinois.
5Departments of Medicine and Human Genetics and Comprehensive Cancer Center, The University of Chicago, Chicago, Illinois.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Noah M. Hahn
6Department of Oncology, Johns Hopkins University, Baltimore, Maryland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
George J. Netto
2Department of Pathology, Johns Hopkins University, Baltimore, Maryland.
4Department of Urology, Johns Hopkins University, Baltimore, Maryland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
David Sidransky
1Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins School of Medicine, Johns Hopkins University, Baltimore, Maryland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mohammad Obaidul Hoque
1Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins School of Medicine, Johns Hopkins University, Baltimore, Maryland.
4Department of Urology, Johns Hopkins University, Baltimore, Maryland.
6Department of Oncology, Johns Hopkins University, Baltimore, Maryland.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: mhoque1@jhmi.edu
DOI: 10.1158/1940-6207.CAPR-14-0251 Published March 2015
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Tables
  • Additional Files
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    A, transformation of HUC1 cells with long-term arsenic exposure: a, morphogic changes: morphology differences were monitored over the entire treatment schedule, using a light microscope (×20). Mock-treated cells and arsenic-treated cells were plated on 6-cm dishes at a density of 200,000 per plate. At 6 months, arsenic-treated HUC1 started to become more rounded and had a tendency to pile on to one another. b, MTT assay: the MTT assay was performed for each month of treatment to determine whether changes in cell proliferation occurred because of arsenic treatment. This figure depicts 2, 4, 6, 8, and 10 months of treated and mock-treated cells for simplicity reasons. Mean and SD were calculated using sample replicate values. c, soft agar assay: anchorage-independent growth was evaluated using soft agar assay. Cell were embedded in agar in triplicates and allowed to grow for 3 weeks. Cell colonies were counted using a light microscope in four different fields and averaged. Cell colonies were then stained with 0.05% ethidium bromide for 24 hours. UV transilluminator was used to determine the number of colonies per well greater than 50 μm in size. Left, colonies in arsenic-treated cells. No colony was observed in arsenic untreated cells (picture not shown). Pictures were taken at random using a digital camera attached to a high-resolution light microscope; right, bar graphs of colonies in different time periods. Statistical differences between 6, 8, and 10 months treated samples and untreated samples were calculated using the Student t test. (*, P < 0.05). d, invasion assay: left, invaded cells after arsenic treatment for 8 and 10 months. Right, graphical representation for the invasion assays performed at 8 and 10 months (UT, untreated; M, month). Invaded cells were counted using a light microscope at 10 different fields and a ×20 objective. Pictures were taken at random. The number of colonies was significantly increased in arsenic-treated samples (*, P < 0.05, Student t test). B, phenotypic observation after withdrawal of arsenic for 2.5 months from 8 months and 10 months arsenic-treated HUC1 cells. a, as determined by the MTT assay, no significant difference of cell viability was observed in 8 and 10 months arsenic-treated and 2.5M untreated cells. b, although no colony was observed in arsenic untreated HUC cells, 8 and 10 months arsenic-treated HUC1 cells retained the properties of anchorage-independent growth even after 2.5 months untreated period. c, similarly, 8 and 10 months arsenic-treated HUC1 cells maintained invasive properties even after culturing these cell for 2.5 months without arsenic. N.S., not significant; As, arsenic.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    A, Western blot analysis of AKT pathway and EMT-related proteins. Bar graphs showed the results of densitomatric analysis (mean ± SD; *, P < 0.05, Student t test). Phosphorylated and total protein for EGFR, AKT, ERK, and PI3K were increased in arsenic-treated HUC1 cells. Cyclin D3 and mTOR were also increased in arsenic-treated HUC1 cells. The molecules that showed significant alterations due to arsenic treatment were bolded. As, arsenic. B, expression levels of miR-200 family in arsenic-exposed HUC1cell culture model. The HUC1 cell line was cultured in the presence of 1 μmol/L As2O3 for 6, 8, and 10 months. To study the reversibility of the arsenic exposal effect to the cells, we withdraw the drug for 2.5 months. Using the Embedded Image method, the data are presented as the fold change in each miRNA expression normalized to mir-222 and relative to the untreated control (HUC1 cell line cultured in the presence of PBS for the same time course). Statistical difference between arsenic-treated and untreated cells were calculated using the Student t test. *, P < 0.05. C, Western blot analysis of two EMT-associated proteins: E-cadherin and Vimentin expression was analyzed using arsenic-treated and untreated HUC1 cells for 6 and 10 months. E-cadherin was significantly decreased in arsenic-treated cells of both 6 and 10 months (P < 0.001 for both 6 and 10 months, Student t test); no changes of expression was observed for Vimentin at 6 months arsenic-treated cells; however, Vimentin expression dramatically increased at 10 months arsenic-treated cells (P < 0.001, Student t test).

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    Average 2−ΔCt of each miRNA expression (A: miR-200a; B: miR-200b; C: miR-200c; and D: miR-205) in urine sample was calculated and plotted after normalization with miR-222. Six groups of samples were listed. All normal urines (1: n = 177) were compared with cancer urines (6: n = 32). As subgroup analyses in normal urines, arsenic unexposed normal urines (2: n = 67) were compared with arsenic-exposed urines (3: n = 110), and nonsmoker normal urines (4: n = 46) were compared with smoker normal urines (5: n = 11). The Mann–Whitney U test was performed and a P value of <0.05 was considered as statistically significant. As for normal versus cancer, miR-200c and miR-205 expressions were significantly downregulated in cancer (P = 0.005 and P < 0.001, respectively). As for arsenic unexposed versus exposed, miR-200a and miR-205 were significantly downregulated in cancer (P = 0.002 and P < 0.001, respectively). As for nonsmoker versus smoker, miR-200c and miR-205 expression was significantly downregulated in cancer (P = 0.044 and P < 0.018, respectively). Notably, the expression of miR-205 was consistently downregulated in arsenic-exposed, smoker and cancer urines.

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    ROC curves for individual miRNA expression in 177 normal and 28 NMIBC urine samples were shown. The y-axis and x-axis denote sensitivity and 1 − specificity, respectively. AUC and the optimal cut off point with maximal sensitivity and specificity on each ROC curve were calculated. The curve of miR-205 showed the high AUC value (0.844) and promising sensitivity (92.9%) and specificity (76.8%) at the optimal cut off point (2−ΔCt=551).

Tables

  • Figures
  • Additional Files
  • Table 1.

    Characteristics of human urine samples tested for miRNA expression

    A. Arsenic-exposed and unexposed normal urine samples
    Arsenic unexposed
    CharacteristicsArsenic exposed (n = 110)Smokers (n = 11)Nonsmokers (n = 46)Total (n = 67a)
    Age, y
     Mean36.859.468.266.5
     Range20—6550—7339–9439–94
    Gender
     Male5483745
     Female563912
    Smoking history
     NeverNot availableN/AN/A46
     0–20 pack yearsNot available5N/A5
     >20–35 pack yearsNot available1N/A1
     >35 pack yearsNot available5N/A5
     UnknownNot availableN/AN/A10
    Water arsenic, μg/L
     <1028N/AN/AN/A
     10–5022N/AN/AN/A
     >5021N/AN/AN/A
     Unknown39N/AN/AN/A
    Creatinine-adjusted urine arsenic, μg/g
     <10035N/AN/AN/A
     100–20038N/AN/AN/A
     >20037N/AN/AN/A
    B. Urothelial carcinoma and arsenic unexposed normal urine samples
    Arsenic unexposed
    CharacteristicsCancer (n = 32)Smokers (n = 11)Nonsmokers (n = 46)Total (n = 67a)
    Age, y
     Mean65.459.468.266.5
     Range36–8450–7339–9439–94
    Gender
     Male2683745
     Female63912
    Stage
     CIS7N/AN/AN/A
     pTa16N/AN/AN/A
     T15N/AN/AN/A
     ≥pT24N/AN/AN/A

    Abbreviation: N/A, not applicable.

    • ↵aIncluded 10 unexposed samples with unknown smoking history.

Additional Files

  • Figures
  • Tables
  • Supplementary Data

    Files in this Data Supplement:

    • Supp Table 1, Supp Table 2 - Supp Table 1, Supp Table 2. Supp Table 1: A.QMSP probe and primers, B.RT-PCR assay. Supplemental Table 2: The summary of notch methylation array findings
    • Supp Figure 1 - Supp Figure 1. Technical validation of Notch Signaling Pathway DNA Methylation PCR Array.
    • Supp Figure 2A - Supp Figure 2A. Promoter methylation is inversely associated with gene expression
    • Supp Figure 2B - Supp Figure 2B. Methylated genes after arsenic treatment
    • Supp Figure 3 - Supp Figure 3. Association of miRNA expression with water arsenic concentration and creatinine adjusted urine arsenic concentration (Mann-Whitney U test).
    • Supp Figure 3 continued - Supp Figure 3 continued
    • Supp Figure 4 - Supp Figure 4. ROC curves for individual micro RNA expression in 177 normal and 32 bladder cancer urine samples were shown.
    • Supp Figure legends - Supp Figure legends
PreviousNext
Back to top
Cancer Prevention Research: 8 (3)
March 2015
Volume 8, Issue 3
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Prevention Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Involvement of Epigenetics and EMT-Related miRNA in Arsenic-Induced Neoplastic Transformation and Their Potential Clinical Use
(Your Name) has forwarded a page to you from Cancer Prevention Research
(Your Name) thought you would be interested in this article in Cancer Prevention Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Involvement of Epigenetics and EMT-Related miRNA in Arsenic-Induced Neoplastic Transformation and Their Potential Clinical Use
Christina Michailidi, Masamichi Hayashi, Sayantan Datta, Tanusree Sen, Kaitlyn Zenner, Oluwadamilola Oladeru, Mariana Brait, Evgeny Izumchenko, Alexander Baras, Christopher VandenBussche, Maria Argos, Trinity J. Bivalacqua, Habibul Ahsan, Noah M. Hahn, George J. Netto, David Sidransky and Mohammad Obaidul Hoque
Cancer Prev Res March 1 2015 (8) (3) 208-221; DOI: 10.1158/1940-6207.CAPR-14-0251

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Involvement of Epigenetics and EMT-Related miRNA in Arsenic-Induced Neoplastic Transformation and Their Potential Clinical Use
Christina Michailidi, Masamichi Hayashi, Sayantan Datta, Tanusree Sen, Kaitlyn Zenner, Oluwadamilola Oladeru, Mariana Brait, Evgeny Izumchenko, Alexander Baras, Christopher VandenBussche, Maria Argos, Trinity J. Bivalacqua, Habibul Ahsan, Noah M. Hahn, George J. Netto, David Sidransky and Mohammad Obaidul Hoque
Cancer Prev Res March 1 2015 (8) (3) 208-221; DOI: 10.1158/1940-6207.CAPR-14-0251
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Authors' Contributions
    • Grant Support
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • IgG Glycosylation and Esophageal Precancerosis
  • Liver cancer treatment and HCV eradication
  • Role of FoxQ1 in bCSC Inhibition by Withaferin A
Show more Research Articles
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Prevention Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Prevention Research
eISSN: 1940-6215
ISSN: 1940-6207

Advertisement